Results 221 to 230 of about 213,015 (316)

Solar‐Powered Remediation of Carcinogenic Chromium(VI) and Methylene Blue Using Ferromagnetic Ni12P5 and Porous Ni12P5‐rGO Nanostructures

open access: yesMetalMat, EarlyView.
In this paper, we have synthesized Ni12P5 and Ni12P5‐rGO using solvothermal method. Studies revealed the ferromagnetic nature of Ni12P5. Sunlight‐driven photocatalytic Cr(VI) reduction and MB degradation were achieved, with formic acid as a hole scavenger.
Omkar V. Vani, Anil M. Palve
wiley   +1 more source

The Antiviral Activity of Polyphenols

open access: yesMolecular Nutrition &Food Research, EarlyView.
Polyphenols demonstrate remarkable antiviral properties by effectively disrupting multiple biochemical processes essential for viral replication. ABSTRACT Polyphenols are secondary metabolites produced by a large variety of plants. These compounds that comprise the class of phenolic acids, stilbenes, lignans, coumarins, flavonoids, and tannins have a ...
Markus Burkard   +5 more
wiley   +1 more source

A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten (EDG‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Sevasemten (EDG‐5506) is an orally administered, investigational small molecule that selectively modulates fast muscle fiber contraction by inhibiting fast myosin ATPase. This study assessed the safety, tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) of sevasemten in healthy adult volunteers (HVs) and adults ...
Joanne Donovan   +11 more
wiley   +1 more source

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT‐1186‐A02)

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is approved in the US for the treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed IV edaravone slows the rate of physical functional decline.
Jeffrey Rothstein   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy